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In the October issue of Biology of Blood and Marrow Transplantation (Vol. 11, No. 10, pp 728-733), the
abstracts from the Second Annual International Umbilical Cord Blood Symposium were prefaced by a
summary of the proceedings, which was written by Dr. John Wagner, Dr. Richard Champlin, and Dr.
Lawrence Petz. The authors’ names and their affiliations were omitted from the summary and should have
read as follows: John Wagner, MD, University of Minnesota, Richard Champlin, MD, M.D. Anderson Cancer
Center, Lawrence D. Petz, MD, StemCyte International Cord Blood Center. The production staff apologize for
this error.
